OBJECTIVE: To determine the quality of life (QOL) and clinical outcome after conservative therapy, embolization (proximal versus distal) or surgery in patients with traumatic splenic injury. Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity of additional therapies, (III) the assessment of splenic function related to splenic morphology (MR imaging) after embolization and (IV) to find the prognostic factors for failure of non-operative management (NOM) in patients with splenic injuries. Finally, with the acquired data from this study a patient-oriented protocol will be provided for the management of traumatic splenic injury. HYPOTHESIS: The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome and splenic function. Embolization will need more additional therapies. Splenic morphology is related to splenic immune function. Expected prognostic factors are age above 40, ISS \>25 and a splenic injury grade of 3 or higher. STUDY DESIGN: A combination of a retrospective and a prospective multicentre cohort study. This protocol involves the prospective part of the study. STUDY POPULATION/DATASET: Patients who enter the participating hospitals between March 2017 and December 2018 with splenic injury will be asked to participate. The follow-up period will be one year with regard to QOL, clinical symptoms and imaging. INTERVENTION: All patients will complete a number of questionnaires at different time points. The patients who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one year after treatment. OUTCOME MEASURES: Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging. SAMPLE SIZE: Approximately 100 patients will be included per year during the inclusion phase. DATA ANALYSIS: With regard to the prospective data linear modelling will be performed. COLLABORATION/CONNECTION: Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen, Isala Zwolle. TIME SCHEDULE: Year 1: literature search and conducting the retrospective study and analyses. Years 1-3: inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data collection and analysing.
Study Type
OBSERVATIONAL
Enrollment
106
All patients will complete a number of questionnaires at different time points. * SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ * 1 week, 1 month, 3, 6 and 12 months after treatment
Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands
Amphia Hospital
Breda, North Brabant, Netherlands
Elisabeth-Twee Steden Hospital
Tilburg, North Brabant, Netherlands
VU University Medical Center
Amsterdam, North Holland, Netherlands
Medical Spectrum Twente
Enschede, Overijssel, Netherlands
Isala
Zwolle, Overijssel, Netherlands
Albert Schweitzer Hospital
Dordrecht, South Holland, Netherlands
Leiden University Medical Center
Leiden, South Holland, Netherlands
Erasmus MC
Rotterdam, South Holland, Netherlands
Maasstad Hospital
Rotterdam, South Holland, Netherlands
Quality of Life: baseline (within 1 week after treatment)
WHOQoL-Bref questionnaire, SF-12 and EQ-5D-5L questionnaires
Time frame: One week after treatment
Quality of life: 1 month follow-up
WHOQoL-Bref questionnaire
Time frame: One month after treatment
Quality of life: 3 months follow-up
WHOQoL-Bref questionnaire
Time frame: Three months after treatment
Quality of life: 6 months follow-up
WHOQoL-Bref questionnaire
Time frame: Six months after treatment
Quality of life: one year follow-up
WHOQoL-Bref questionnaire
Time frame: One year after treatment
Change in health status: SF-12
SF-12 questionnaire
Time frame: One week, 1 month and 3, 6 and 12 months after treatment
Change in health related quality of life: EQ-5D-5L
EQ-5D-5L questionnaire
Time frame: One week, 1 month and 3, 6 and 12 months after treatment
Clinical Outcome
Data obtained from the patient records (e.g. complications, need for re-intervention, hospital stay, return to daily activities)
Time frame: One year follow-up
Cost-effectiveness
The overall cost-effectiveness will be assessed with the iPCQ and iMCQ questionnaires, completed at different time points
Time frame: One year follow-up
Imaging Outcome after Embolization (one month after treatment)
Splenic morphological characteristics (e.g. volume, necrosis, splenosis, calcifications or chronic infarction morphology)
Time frame: One month after embolization
Imaging Outcome after Embolization (one year after treatment)
Splenic morphological characteristics (e.g.volume, necrosis, splenosis, calcifications or chronic infarction morphology)
Time frame: One year after embolization
Splenic Artery Embolization characteristics
Difference between proximal versus distal embolization
Time frame: One year follow-up
Prognostic factors for failure of Non-Operative Management
A recent study suggests that there are prognostic factors for failure of NOM in the treatment of adults with (blunt) splenic injury. Strong evidence exists for: age of 40 years or above, Injury Severity Score (ISS) of 25 or greater and American Association for the Surgery of Trauma (AAST) splenic injury grade of 3 or greater.
Time frame: One year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.